SCHEMBL6764034

SCHEMBL6764034

CN(C)CCCCNCc1ccc(C#N)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCN8A Q9UQD0 1/20 0.53
CACNA1B Q00975 3/20 0.52
LOXL2 Q9Y4K0 1/20 0.51
CA12 O43570 1/20 0.46
CA1 P00915 1/20 0.46
CA2 P00918 1/20 0.46
CA4 P22748 1/20 0.46
CA9 Q16790 1/20 0.46
CHRM2 P08172 4/20 0.45
HRH3 Q9Y5N1 2/20 0.44
HRH4 Q9H3N8 1/20 0.44
CYP2A6 P11509 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.41
MAOA P21397 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP2D6 P10635 1/20 0.41
CYP2C19 P33261 1/20 0.41
TERT O14746 1/20 0.40
CCNA2 P20248 1/20 0.40
CDK2 P24941 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6764095 0.95 SCN8A (0.55) SCN8ACACNA1BLOXL2CA12CA1
SCHEMBL2207581 0.85 SCN8A (0.51) SCN8ALOXL2CA12CA1CA2
SCHEMBL2201948 0.84 SCN8A (0.50) SCN8ALOXL2CA12CA1CA2
Hydrochloric Acid SCHEMBL2199547 0.84 SCN8A (0.50) SCN8ALOXL2CA12CA1CA2
Hydrochloric Acid SCHEMBL2205193 0.82 SCN8A (0.49) SCN8ALOXL2CA12CA1CA2
SCHEMBL13985127 0.81 LOXL2 (0.65) SCN8ACACNA1BLOXL2CA12CA1
SCHEMBL2828109 0.80 SCN8A (0.58) SCN8ACACNA1BLOXL2CA12CA1
SCHEMBL10938395 0.80 SCN8A (0.49) SCN8ACACNA1BLOXL2CA12CA1
SCHEMBL10938273 0.80 SCN8A (0.49) SCN8ACACNA1BLOXL2CA12CA1
SCHEMBL29912750 0.79 LOXL2 (0.65) SCN8ACACNA1BLOXL2CA12CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040063725-A1 Novel n(phenylsulphonyl)glycine derivatives and their therapeutic use LABORATORIES FOURNIER S.A. (FR) 2004-04-01 US disclosed
CN-1484633-A N (phenylsulphonyl) glycine derivatives and their therapentic use ʵ���Ҹ���Ү��˾ 2004-03-24 CN disclosed
EP-1351928-A2 NOVEL N(PHENYLSULPHONYL)GLYCINE DERIVATIVES AND THEIR THERAPEUTIC USE LABORATOIRES FOURNIER S.A. (FR) 2003-10-15 EP disclosed
WO-2002053516-A2 N(PHENYLSULPHONYL)GLYCINE DERIVATIVES AND THEIR THERAPEUTIC USE LABORATOIRES FOURNIER SA (FR) 2002-07-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040063725-A1 Novel n(phenylsulphonyl)glycine derivatives and their therapeutic use GLS, GLS2, GLRB SCN8A 2257/4885CACNA1B 2365/4885LOXL2 446/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.